01 August 2021
: Case report 
COVID-19 and Hepatic Artery Thrombosis: A Case Report
Unusual clinical course, Challenging differential diagnosis, Management of emergency care
Carlos Alexandre Antunes de Brito12ABCDEF*, José Ricardo Bandeira de Oliveira Filho3ABCDEF, Diogo Torres Marques4ABCDEF, Maria do Carmo Lencastre5ABCDEF, José Roberto de Almeida1ABCDEF, Edmundo Pessoa Lopes1ABCDEFDOI: 10.12659/AJCR.932531
Am J Case Rep 2021; 22:e932531
Table 1. Laboratory test results for the patient when the hepatic artery thrombosis was diagnosed.
| Variable (normal values) | 16th day of illness |
|---|---|
| White blood cells 10/mm (4–10) | 8.760 |
| Neutrophils 10/mm (1.6–7) | 5957 |
| Lymphocytes 10/mm (1.5–4.5) | 1927 |
| Hemoglobin g/dl (11.5–15) | 13,3 |
| Platelets 10/mm (150–450) | 212 |
| C-reactive protein mg/dl (<0.5) | 1,8 |
| AST U/L (10–37) | 32 |
| ALT U/L (5–45) | 25 |
| Bilirubin mg/dl (0.3–1.2) | 0,8 |
| Alkaline phosphatase U/L (46–116) | 75 |
| Gamma GT U/L (1–24) | 56 |
| LDH U/L (120–246) | 226 |
| Lipase U/L (12–53) | 52 |
| D-Dimer ng/ml (<500) | 2541 |
| Fibrinogen mg/dl (200–400) | 454 |
| Prothombin time ratio (0.80–1.2) | 1.0 |
| Fator V de Leiden mutation R506Q | Absent |
| Prothrombin G20210A mutation | Absent |
| Anti-beta2 glycoprotein I (IgG) U/ml (negative <7) | 2,9 |
| Anti-beta2 glycoprotein I (IgM)U/ml (negative <7) | <2,9 |
| Rheumatoid factor | Neg |
| Antinuclear antibody | Neg |
| Anticardiolipin IgG (GPL <10) | 0,8 |
| Homocysteine mcmol/L (4.4–13.56) | 13 |
| Protein C% (70–140) | 130 |
| Protein S% (72–112) | 110 |
| Antithrombin (82–112%) | 89 |
| ALT – alanine transaminase; gamma-GT – gamma-glutamyltransferase; LDH – lactate-dehydrogenase. | |